News Early filing gives GSK a boost in COPD Compelling data from FULFIL study puts GSK in pole position
News Synairgen under the weather after AZ halts asthma trial AZ assessing drug's future following trial disappointment.
News Faron moves ahead with "shock lung" drug Finnish firm eyes first drug for acute respiratory distress syndrome.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
